DelveInsight’s “Community-Acquired Bacterial Pneumonia (CABP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Community-Acquired Bacterial Pneumonia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Community-Acquired Bacterial Pneumonia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Community-Acquired Bacterial Pneumonia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Community-Acquired Bacterial Pneumonia (CABP): An Overview
Community-acquired bacterial pneumonia (CABP) is a common, acute, severe infection of the lung parenchyma. It is a major cause of mortality in adults. It is one of the most frequent respiratory illnesses among various infections triggering sepsis. The Global Burden of Disease Study identified lower respiratory tract infection (LRTI) as the second most common cause of death and years of life lost. Microbiologically, bacteria are common agents in pneumonia, with Streptococcus pneumoniae being the most common cause worldwide.
Streptococcus pneumoniae is a bacteria most often responsible for CAP in adults worldwide. Some other common bacteria that cause CAP are Haemophilus influenza and Mycoplasma pneumoniae. Pneumonia caused by chlamydia and mycoplasma is often clinically indistinguishable from other pneumonia.
Some antibiotics have been approved, which will expand the treatment options for CAP, particularly in patients with primary complications. Common antimicrobials used to treat CAP include macrolides (alone or in combination with β-lactams), amoxicillin (alone or combined with a macrolide), fluoroquinolones, and third-generation cephalosporins combined with a macrolide.
Risk factors for CABP are largely defined by conditions that reduce the efficacy of the normal mechanisms of lung immunity. The dominant risk factor is age, with the incidence of CAP increasing markedly in patients who are over 65 years of age. As a consequence, CAP affects 2% of people over 85 years of age each year and, in a recent British Thoracic Society (BTS) UK-wide audit of CAP, the mean age of patients was 76 years.
Community-Acquired Bacterial Pneumonia (CABP) Market Key Facts
-
The total 7MM Incident cases of Community-Acquired Bacterial Pneumonia (CABP) were 6,961,838 in 2022.
-
The estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. (Regunath et al., 2020)
-
Worldwide, CAP affects 3–4 million people each year with high morbidity and mortality, particularly among elderly patients. The WHO Global Burden of Disease study reported that lower respiratory tract infections (LRTIs), including CAP, cause approximately 429.2 million episodes of illness globally. (Sharma et al. 2020).
-
Some of the key players in the market include Combioxin, BioAegis Therapeutics, Biotest, Tigenix, and others.
Community-Acquired Bacterial Pneumonia (CABP) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Community-Acquired Bacterial Pneumonia pipeline therapies. It also thoroughly assesses the Community-Acquired Bacterial Pneumonia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Community-Acquired Bacterial Pneumonia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Community-Acquired Bacterial Pneumonia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Community-Acquired Bacterial Pneumonia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Community-Acquired Bacterial Pneumonia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Community-Acquired Bacterial Pneumonia Epidemiology, Segmented as –
-
Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
-
Diagnosed and Treatable Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
-
Age-specific Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
-
Gender-specific Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM (2019–2032)
Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to be launched during the study period. The analysis covers the Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Community-Acquired Bacterial Pneumonia drugs based on their sale and market share.
The report also covers the Community-Acquired Bacterial Pneumonia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Community-Acquired Bacterial Pneumonia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Community-Acquired Bacterial Pneumonia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/rett-syndrome-market
Community-Acquired Bacterial Pneumonia Therapeutics Analysis
Although most CABP patients are treated empirically, the best treatment choice remains unclear. The appropriate choice of treatment is antibiotic. Some of the drugs that are approved for the treatment of CABP include Nuzyra (omadacycline), Baxdela (delafloxacin), and Xenleta (lefamulin). In addition, the drugs approved for hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP) comprises Recarbrio (Cilastatin/imipenem/relebactam), Fetroja (cefiderocol), Avycaz (ceftazidime-avibactam), Vibativ (telavancin), and Zerbaxa (ceftolozane + tazobactam), among others.
Moreover, the treatment of CABP has become challenging with the changing safety profiles and efficacy of well-established antibiotics, as well as limited new therapeutic options.
The Community-Acquired Bacterial Pneumonia market is anticipated to evolve immensely in the coming years owing to the launch of upcoming therapies, the rise in healthcare spending across the world, and the increased patient pool. Some of the key players in the market include Combioxin, BioAegis Therapeutics, Biotest, Tigenix, and others.
“On June 14, 2023, Eagle Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, the anti-infective agent being developed to treat severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care.”
Community-Acquired Bacterial Pneumonia Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Community-Acquired Bacterial Pneumonia market include Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, TiGenix and others.
Emerging and Marketed Community-Acquired Bacterial Pneumonia Therapies Covered in the Report Include:
-
CAL02: Eagle Pharmaceutical
-
Xenleta (lefamulin): Nabriva Therapeutics
-
Gelsolin: BioAegis Therapeutics
-
Trimodulin: Biotest
-
Cx611: Tigenix
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/rett-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Community-Acquired Bacterial Pneumonia Competitive Intelligence Analysis
4. Community-Acquired Bacterial Pneumonia Market Overview at a Glance
5. Community-Acquired Bacterial Pneumonia Disease Background and Overview
6. Community-Acquired Bacterial Pneumonia Patient Journey
7. Community-Acquired Bacterial Pneumonia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Community-Acquired Bacterial Pneumonia Treatment Algorithm, Current Treatment, and Medical Practices
9. Community-Acquired Bacterial Pneumonia Unmet Needs
10. Key Endpoints of Community-Acquired Bacterial Pneumonia Treatment
11. Community-Acquired Bacterial Pneumonia Marketed Therapies
12. Community-Acquired Bacterial Pneumonia Emerging Drugs and Latest Therapeutic Advances
13. Community-Acquired Bacterial Pneumonia Seven Major Market Analysis
14. Attribute Analysis
15. Community-Acquired Bacterial Pneumonia Market Outlook (In US, EU5, and Japan)
16. Community-Acquired Bacterial Pneumonia Companies Active in the Market
17. Community-Acquired Bacterial Pneumonia Access and Reimbursement Overview
18. KOL Views on the Community-Acquired Bacterial Pneumonia Market
19. Community-Acquired Bacterial Pneumonia Market Drivers
20. Community-Acquired Bacterial Pneumonia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/rett-syndrome-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Primary Open Angle Glaucoma (POAG) Market
“Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Primary Open Angle Glaucoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the POAG market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology